US EditionCancer Therapy in Space: Rebexinib Trials Show Double Effectiveness
Summary by se7en.ws
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Aspera Biomedicine, in collaboration with the Sanford Stem Cell Institute (SSCI) at the University of California, San Diego, has completed a significant preclinical testing phase for rebexinib. This drug targets the ADAR1 gene, which helps cancer cells clone and protect them from immune attacks. Rebexinib has already received FDA approval to advance to clinical trials, receiving Investigational New Drug designation... The post Cancer Therapy in …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
